# Nuclide record oliver-sartor (person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/people/oliver-sartor/>
  a schema:Person ;
  nuclide:kind "person" ;
  schema:identifier "oliver-sartor" ;
  schema:name "A. Oliver Sartor"@en ;
  schema:description "Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer."@en ;
  schema:url <https://nuclide.cc/people/oliver-sartor/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Oliver_Sartor> ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium> ;
  nuclide:tag "prostate", "radioligand", "trialist" ;
  schema:jobTitle "Professor of Medical Oncology and Urology, Mayo Clinic" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ra-223/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/psma-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/> ;
  nuclide:institutions <https://nuclide.cc/institutions/mayo-clinic/> ;
  nuclide:trials <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/trials/alsympca/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-vision-nejm-2021/> ;
  schema:affiliation <https://nuclide.cc/institutions/mayo-clinic/> .